Sanofi (SAN) Fair Value & Analysis
Financial Services · CA · Market cap 654B PLN
Fair value as of: Jun 26, 2026
From 17 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from 10.42 PLN to 12.73 PLN (+22.2%) since Jun 24, 2026. Share price +12.0% over the past month.
Price vs Fair Value (12 months)
12‑month range 28.21 PLN – 50.81 PLN · fair‑value band 9.55 PLN – 15.91 PLN · the 49.95 PLN price screens above the 12.73 PLN fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sanofi (SAN) currently trades at 49.95 PLN, while our model-based Fair Value estimate is 12.73 PLN — implying the stock looks roughly 74.5% overvalued today. We read business quality at 94/100 (high quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Sanofi generated revenue of 47.4B PLN at a net margin of 34.1%. Revenue grew 4.6% year over year. It earns a return on equity of 12.9%. Net debt stands at 145B PLN. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseas…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sanofi reported revenue of 60.0B PLN in FY2025 versus 39.0B PLN in FY2021, a compound +11.4%/yr. Reported net income was 14.1B PLN in FY2025, compounding +14.8%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Banks - Diversified stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JPMorgan Chase & Co JPM | C$42.65 | C$18.12 | -58% |
| Industrial and Commercial Bank of China Limited IDCBY | $17.83 | $35.66 | +100% |
| Bank of America Corporation BOFA | C$28.67 | C$15.23 | -47% |
| China Construction Bank Corporation 601939 | ¥10.22 | ¥20.44 | +100% |
| Agricultural Bank of China Limited 601288 | ¥6.36 | ¥12.72 | +100% |
| HSBC Holdings HSBC | $86.16 | $72.46 | -16% |
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is Sanofi (SAN) undervalued?
What is the fair value of SAN?
What is the quality score of SAN?
What is the revenue of Sanofi (SAN)?
What is the net profit margin of SAN?
Does Sanofi pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.